摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-(2-Furyl)-9-methyl-2-(3-morpholino-1-propynyl)-9H-6-purinamine | 232252-86-7

中文名称
——
中文别名
——
英文名称
8-(2-Furyl)-9-methyl-2-(3-morpholino-1-propynyl)-9H-6-purinamine
英文别名
8-(Furan-2-yl)-9-methyl-2-(3-morpholin-4-ylprop-1-ynyl)purin-6-amine
8-(2-Furyl)-9-methyl-2-(3-morpholino-1-propynyl)-9H-6-purinamine化学式
CAS
232252-86-7
化学式
C17H18N6O2
mdl
——
分子量
338.369
InChiKey
GYQRLZBLHZEVPD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    95.2
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES
    申请人:Eisai Co., Ltd.
    公开号:EP1054012A1
    公开(公告)日:2000-11-22
    The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonistic action. A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof has an adenosine A2 receptor antagonistic action and is useful for prevention or therapy of diabetes mellitus and diabetic complications. In addition, adenosine A2 receptor antagonists having different structures from those of the compounds described above, for example KW6002, are also effective for prevention or therapy of diabetes mellitus and diabetic complications. In the formula, W is -CH2CH2-, -CH=CH- or -C≡C-; R1 is: (in the formula, X is hydrogen atom, hydroxyl group, a lower alkyl group, a lower alkoxy group, etc.; and R5 and R6 are the same as or different from each other and each represents hydrogen atom, a lower alkyl group, a cycloalkyl group, etc.) and the like; R2 is an amino group, etc. which may be substituted with a lower alkyl group, etc.; R3 is a cycloalkyl group, an optionally substituted aryl group, etc.; and R4 is a lower alkyl group, etc.
    本发明提供了一种基于腺苷 A2 受体拮抗作用的新型糖尿病和糖尿病并发症预防或治疗剂。 由式(I)代表的嘌呤化合物、其药理上可接受的盐或其水合物具有腺苷 A2 受体拮抗作用,可用于预防或治疗糖尿病和糖尿病并发症。此外,与上述化合物结构不同的腺苷 A2 受体拮抗剂,例如 KW6002,也可有效预防或治疗糖尿病和糖尿病并发症。 式中,W为-CH2CH2-、-CH=CH-或-C≡C-;R1为: (式中,X 是氢原子、羟基、低级烷基、低级烷氧基等;R5 和 R6 彼此相同或不同,各自代表氢原子、低级烷基、环烷基等)等;R2 是可被低级烷基等取代的氨基等;R3 是环烷基、任选取代的芳基等;R4 是低级烷基等。
  • US6579868B1
    申请人:——
    公开号:US6579868B1
    公开(公告)日:2003-06-17
查看更多